AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia
The HEAL-IST trial is a prospective, multicenter, single-arm study of 142 patients at up to 40 centers in
“Symptomatic IST is a serious arrhythmia that dramatically decreases the quality of life in predominantly younger adults, and more specifically, young women,” said Dr. LaMeir, Professor and Head of Cardiac Surgery at University Hospital Brussels, and co-principal investigator in the HEAL-IST trial. “Further, since current antiarrhythmic drug treatment has limited long-term effect, and societal guidelines do not advise sinus node ablation or modulation, this landmark study of sinus node sparing hybrid ablation has the potential to establish a standard of care for these patients.”
“We believe that cardiac surgeons and electrophysiologists working together is a safe and highly effective way to treat complex arrhythmias,” said
“IST is a common disease that is often under or mis-diagnosed,” said
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005182/en/
Investor Relations
Chief Financial Officer
(513) 755-5334
[email protected]
Media Relations
Vice President, Corporate Marketing & Communications
(612) 605-3311
[email protected]
Source: AtriCure, Inc.